# Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

> **NCT07221578** · PHASE3 · RECRUITING · sponsor: **Vanda Pharmaceuticals** · enrollment: 500 (estimated)

## Conditions studied

- Social Anxiety Disorder (SAD)

## Interventions

- **DRUG:** VQW-765
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07221578
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-22
- **Primary completion:** 2026-12
- **Final completion:** 2027-04
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221578, "Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07221578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*